Comparison · NCT04545866-deaths
BUDE vs SURF: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BUDE vs SURF: deaths from any cause. Trial comparisons, record NCT04545866-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04545866-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.152 | 0.117 | 0.195 | wilson | |
| Risk in group 2 | 0.132 | 0.0992 | 0.174 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0196 | -0.0348 | 0.0739 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.784 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.753 | 1.83 | log | |
| Number needed to harm, for one more death from any cause on BUDE than on SURF | 50.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BUDE | Budesonide (Pulmicort nebulizing suspension) 1 ml/kg + Surfactant (poractant alfa; Curosurf) 2.5 ml/kg | 49 | 323 | EG000 |
| Group 2 | SURF | Surfactant (poractant alfa; Curosurf) 2.5 ml/kg | 42 | 318 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Adverse events were monitored from treatment through 7 days (168 hours) post-treatment, or treatment through 30 days (720 hours) post-treatment for SIP and PVL. All-cause mortality was monitored from randomization through 36 weeks PMA.
Source ClinicalTrials.gov
Trial
- Title
- The Budesonide in Babies (BiB) Trial
- NCT number
- NCT04545866
- Phases
- PHASE3
- Conditions
- Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
- Interventions
- budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
- Lead sponsor
- NICHD Neonatal Research Network
- Results first posted
- 2025-11-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04545866?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04545866-deaths